Echarki Zerif
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Echarki Zerif has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Abdelouahed Khalil
Department of Medicine, Geriatrics Service, Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, QC J1H 4N4, Canada
2 shared publications - Denis Gris
Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences (FMSS), University of Sherbrooke, Sherbrooke, Quebec, J1H 5N4, Canada
2 shared publications - Hicham Berrougui
Geriatrics Unit, Department of Medicine, Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, QC J1H 4N4, Canada
2 shared publications - Olaf van Tellingen
The Netherlands Cancer Institute
2 shared publications - Ton Bunt
Izumi Biosciences, Inc., Lexington, MA, USA
2 shared publications - Alan A. Cohen
Department of Environmental Health Sciences, Butler Columbia Aging Center, Mailman School of Public Health, Columbia University, New York, NY, USA
1 shared publication
Latest Publications
- Open Access
- 30 April 2026
- Published by Elsevier in SSRN Electronic Journal
Time-Dependent Effects of Elacridar on P-glycoprotein (ABCB1) Activity in Neuroglioma Cells
BackgroundATP-Binding cassette (ABC) transporters such as P-glycoprotein (P-gp)/ABCB1 actively efflux xenobiotics, including therapeutic agents, leading to drug resistance. While elacridar is a well-established P-gp inhibitor in peripheral tissues, its effects on the central nervous system, particularly on neuroglioma P-gp, remain incompletely understood.PurposeWe aimed to evaluate the time-dependent inhibition of P-gp by elacridar in the H4 neuroglioma cells.MethodsP-gp activity was studied by measuring the intracellular accumulation of rhodamine 123 (Rho123) using flow cytometry. We conducted in-silico analyses to explore the biological interactions between elacridar and the P-gp transporters.ResultsElacridar exhibited a biphasic, time-dependent modulation of P-gp activity. At early time points (1/2h and 1h), elacridar unexpectedly decreased the intracellular concentration of Rho123. This effect was reversed at 4h, when elacridar significantly increased Rho123 accumulation (p<0.05). However, this inhibitory effect progressively declined at 12h and was strongly abolished by 24 h.ConclusionOverall, these results are in favour of a dual, time-dependent modulation of elacridar on neuroglioma P-gp activity. Our findings provided the first functional evidence of P-gp-mediated efflux in neuroglioma cells, highlighting its potential role in regulating drug disposition in the central nervous system. This may have important implications for the treatment of neurodegenerative diseases.
- 30 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTime-Dependent Effects of Elacridar on P-glycoprotein (ABCB1) Activity in Neuroglioma Cells
BackgroundATP-Binding cassette (ABC) transporters such as P-glycoprotein (P-gp)/ABCB1 actively efflux xenobiotics, including therapeutic agents, leading to drug resistance. While elacridar is a well-established P-gp inhibitor in peripheral tissues, its effects on the central nervous system, particularly on neuroglioma P-gp, remain incompletely understood.PurposeWe aimed to evaluate the time-dependent inhibition of P-gp by elacridar in the H4 neuroglioma cells.MethodsP-gp activity was studied by measuring the intracellular accumulation of rhodamine 123 (Rho123) using flow cytometry. We conducted in-silico analyses to explore the biological interactions between elacridar and the P-gp transporters.ResultsElacridar exhibited a biphasic, time-dependent modulation of P-gp activity. At early time points (1/2h and 1h), elacridar unexpectedly decreased the intracellular concentration of Rho123. This effect was reversed at 4h, when elacridar significantly increased Rho123 accumulation (p<0.05). However, this inhibitory effect progressively declined at 12h and was strongly abolished by 24 h.ConclusionOverall, these results are in favour of a dual, time-dependent modulation of elacridar on neuroglioma P-gp activity. Our findings provided the first functional evidence of P-gp-mediated efflux in neuroglioma cells, highlighting its potential role in regulating drug disposition in the central nervous system. This may have important implications for the treatment of neurodegenerative diseases.
- 20 March 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 105 (2) , 464-480
Neuroprotective effects of SGLT2 inhibitors empagliflozin and dapagliflozin on Aβ 1–42 -induced neurotoxicity and neuroinflammation in cellular models of Alzheimer's disease
Background: Alzheimer's disease (AD) is a chronic brain degenerative disease that leads to dementia. Objective: The aim of the present study is to investigate the neuroprotective impact of sodium-glucose cotransporter-2 inhibitors (SGLT2i) (empagliflozin and dapagliflozin) on tau phosphorylation, oxidative stress, and neuroinflammation. Methods: We used MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) assay, annexin-V-FITC kit, and DCFH-DA (dichloro-dihydro-fluorescein diacetate) to respectively evaluate the effect of the SGLT2i (empagliflozin and dapagliflozin) on amyloid-β (Aβ) 1–42 -induced neuronal death, apoptosis, and oxidative stress. The expression of NLRP3-inflammasome, phospho-Tau181, glycogen synthase kinase-3 beta (GSK-3β), cyclin-dependent kinase 5 (CdK5), and histone deacetylase 6 (HDAC6), was quantified by flow cytometry. Drug distribution in the mice's brains was assessed by liquid chromatography-mass spectrometry (LC-MS). Results: Aβ 1–42 significantly reduced cell viability and increased apoptosis, which was reversed by using gliflozins. SGLT2i significantly reduced Aβ 1–42 -induced reactive oxygen species generation, downregulated NLRP3-inflammasome, and diminished tau pathology. Mechanistically, the last effect involved the modulation of GSK-3β and CdK5 protein expression. However, the tested treatments did not modify the Aβ 1–42 -stimulating effect of HDAC6. Gliflozins are substrates of drug transporters ATP-binding cassette sub-family B member 1 and/or ATP binding cassette subfamily G member 2 (ABCB1 and ABCG2), and Elacridar significantly enhances their brain distribution. Conclusions: SGLT2i empagliflozin and dapagliflozin exhibited neuroprotective actions against human Aβ 1–42 -induced neurotoxicity.
- 20 March 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 105 (2) , 464-480
Neuroprotective effects of SGLT2 inhibitors empagliflozin and dapagliflozin on Aβ 1–42 -induced neurotoxicity and neuroinflammation in cellular models of Alzheimer's disease
Background: Alzheimer's disease (AD) is a chronic brain degenerative disease that leads to dementia. Objective: The aim of the present study is to investigate the neuroprotective impact of sodium-glucose cotransporter-2 inhibitors (SGLT2i) (empagliflozin and dapagliflozin) on tau phosphorylation, oxidative stress, and neuroinflammation. Methods: We used MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) assay, annexin-V-FITC kit, and DCFH-DA (dichloro-dihydro-fluorescein diacetate) to respectively evaluate the effect of the SGLT2i (empagliflozin and dapagliflozin) on amyloid-β (Aβ) 1–42 -induced neuronal death, apoptosis, and oxidative stress. The expression of NLRP3-inflammasome, phospho-Tau181, glycogen synthase kinase-3 beta (GSK-3β), cyclin-dependent kinase 5 (CdK5), and histone deacetylase 6 (HDAC6), was quantified by flow cytometry. Drug distribution in the mice's brains was assessed by liquid chromatography-mass spectrometry (LC-MS). Results: Aβ 1–42 significantly reduced cell viability and increased apoptosis, which was reversed by using gliflozins. SGLT2i significantly reduced Aβ 1–42 -induced reactive oxygen species generation, downregulated NLRP3-inflammasome, and diminished tau pathology. Mechanistically, the last effect involved the modulation of GSK-3β and CdK5 protein expression. However, the tested treatments did not modify the Aβ 1–42 -stimulating effect of HDAC6. Gliflozins are substrates of drug transporters ATP-binding cassette sub-family B member 1 and/or ATP binding cassette subfamily G member 2 (ABCB1 and ABCG2), and Elacridar significantly enhances their brain distribution. Conclusions: SGLT2i empagliflozin and dapagliflozin exhibited neuroprotective actions against human Aβ 1–42 -induced neurotoxicity.